Polyethylene glycol modified endostatin inhibitor composition
The invention relates to a polyethylene glycol modified endostatin inhibitor composition which comprises polyethylene glycol endostatin, a protector and a buffer system, wherein the dosage ratio of the polyethylene glycol endostatin to the protector is (1:10)-(10:1); and the buffer system is a phosp...
Gespeichert in:
Hauptverfasser: | , , , , , , |
---|---|
Format: | Patent |
Sprache: | chi ; eng |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The invention relates to a polyethylene glycol modified endostatin inhibitor composition which comprises polyethylene glycol endostatin, a protector and a buffer system, wherein the dosage ratio of the polyethylene glycol endostatin to the protector is (1:10)-(10:1); and the buffer system is a phosphate buffer system. In the preparation process, when the phosphate buffer system is adopted as a buffer agent, the pH value of an obtained frozen-dry preparation is slightly changed, and storage and shelf stability of a product can be well benefited.
本发明涉及一种聚乙二醇修饰的血管内皮抑制素组合物,所述组合物包含聚乙二醇化血管内皮抑制素、保护剂和缓冲体系,其中所述的聚乙二醇化血管内皮抑制素与保护剂的质量比为1:10~10:1;所述的缓冲体系为磷酸盐缓冲体系;在制备过程中,当使用磷酸盐缓冲体系作为缓冲剂时,获得的冻干制剂的pH变化较小,十分有利于产品的储藏和货架稳定性。 |
---|